Identification of NEK7 inhibitors: structure based virtual screening, molecular docking, density functional theory calculations and molecular dynamics simulations
- PMID: 35983608
- DOI: 10.1080/07391102.2022.2113563
Identification of NEK7 inhibitors: structure based virtual screening, molecular docking, density functional theory calculations and molecular dynamics simulations
Abstract
NEK7 is a NIMA related-protein kinase that plays a crucial role in spindle assembly and cell division. Dysregulation of NEK7 protein leads to development and progression of different types of malignancies including colon and breast cancers. Therefore, NEK7 could be considered as an attractive target for anti-cancer drug discovery. However, few efforts have been made for the development of selective inhibitors of NIMA-related kinase but still no FDA approved drug is known to selectively inhibit the NEK7 protein. Dacomitinib and Neratinib are two Enamide derivatives that were approved for treatment against non-small cell lung cancer and breast cancer respectively. Drug repurposing is a time and cost-efficient method for re-evaluating the activities of previously authorized medications. Thus, the present research involves the repurposing of two FDA-approved medications via comprehensive in silico approach including Density functional theory (DFTs) studies which were conducted to determine the electronic properties of the Dacomitinib and Neratinib. Afterward, binding orientation of selected drugs inside NEK7 activation loop was evaluated through molecular docking approach. Selected drugs exhibited potential molecular interactions engaging important amino acid residues of active site. The docking score of Dacomitinib and Neratinib was -30.77 and -26.78 kJ/mol, respectively. The top ranked pose obtained from molecular docking was subjected to Molecular Dynamics (MD) Simulations for investigating the stability of protein-ligand complex. The RMSD pattern revealed the stability of protein-ligand complex throughout simulated trajectory. In conclusion, both drugs displayed inhibitory efficacy against NEK7 protein and provide a prospective therapy option for malignant malignancies linked with NEK7.
Keywords: FDA; MD simulations; Molecular docking; NEK7; density functional theory.
Similar articles
-
Deep Learning and Structure-Based Virtual Screening for Drug Discovery against NEK7: A Novel Target for the Treatment of Cancer.Molecules. 2022 Jun 25;27(13):4098. doi: 10.3390/molecules27134098. Molecules. 2022. PMID: 35807344 Free PMC article.
-
Revisiting the inhibitory potential of protein kinase inhibitors against NEK7 protein via comprehensive computational investigations.Sci Rep. 2023 Mar 15;13(1):4304. doi: 10.1038/s41598-023-31499-7. Sci Rep. 2023. PMID: 36922575 Free PMC article.
-
In silico study to identify novel NEK7 inhibitors from natural sources by a combination strategy.Mol Divers. 2025 Feb;29(1):139-162. doi: 10.1007/s11030-024-10838-4. Epub 2024 Apr 10. Mol Divers. 2025. PMID: 38598164
-
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.Pharmacol Res. 2019 Jan;139:395-411. doi: 10.1016/j.phrs.2018.11.014. Epub 2018 Nov 27. Pharmacol Res. 2019. PMID: 30500458 Review.
-
Repurposing of FDA-approved drugs as dual-acting MAO-B and AChE inhibitors against Alzheimer's disease: An in silico and in vitro study.J Mol Graph Model. 2023 Jul;122:108471. doi: 10.1016/j.jmgm.2023.108471. Epub 2023 Apr 14. J Mol Graph Model. 2023. PMID: 37087882 Review.
Cited by
-
Developing Novel Beta-Secretase Inhibitors in a Computer Model as a Possible Treatment for Alzheimer's Disease.Adv Pharmacol Pharm Sci. 2025 Mar 31;2025:5528793. doi: 10.1155/adpp/5528793. eCollection 2025. Adv Pharmacol Pharm Sci. 2025. PMID: 40201042 Free PMC article.
-
Deep Learning and Structure-Based Virtual Screening for Drug Discovery against NEK7: A Novel Target for the Treatment of Cancer.Molecules. 2022 Jun 25;27(13):4098. doi: 10.3390/molecules27134098. Molecules. 2022. PMID: 35807344 Free PMC article.
-
Efficient synthesis of N-(ethylcarbamothioyl)-1-naphthamide: X-ray structure, Hirshfeld surface analysis, DFTs, and molecular modelling investigations as selective inhibitor of alkaline phosphatase.BMC Chem. 2025 Jul 2;19(1):182. doi: 10.1186/s13065-025-01525-y. BMC Chem. 2025. PMID: 40605008 Free PMC article.
-
Design, Synthesis, Kinetic Analysis and Pharmacophore-Directed Discovery of 3-Ethylaniline Hybrid Imino-Thiazolidinone as Potential Inhibitor of Carbonic Anhydrase II: An Emerging Biological Target for Treatment of Cancer.Biomolecules. 2022 Nov 16;12(11):1696. doi: 10.3390/biom12111696. Biomolecules. 2022. PMID: 36421710 Free PMC article.
-
Synthesis, DFT and molecular docking of novel (Z)-4-bromo-N-(4-butyl-3 (quinolin-3-yl)thiazol-2(3H)-ylidene)benzamide as elastase inhibitor.BMC Chem. 2023 Aug 7;17(1):95. doi: 10.1186/s13065-023-00985-4. BMC Chem. 2023. PMID: 37550776 Free PMC article.
LinkOut - more resources
Full Text Sources
Miscellaneous